Needham analyst Michael Matson reiterated a Buy rating on Artivion today and set a price target of $58.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors including Artivion’s impressive financial performance in the third quarter of 2025. The company exceeded market expectations with its revenue and EBITDA, and subsequently raised its revenue and EBITDA guidance for the year. This positive outlook is supported by significant growth in key product lines such as On-X and stent grafts, which saw substantial increases in constant currency terms.
Geographically, Artivion experienced robust growth across all major regions, with North America, Asia Pacific, and EMEA all showing strong performance. Additionally, the successful launch of AMDS and progress in the company’s pipeline projects like NEXUS and Arcevo further bolster the company’s growth trajectory. These factors contribute to the confidence in Artivion’s future prospects, justifying the Buy rating and an increased price target.
In another report released yesterday, Lake Street also maintained a Buy rating on the stock with a $45.00 price target.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AORT in relation to earlier this year.